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Introduction: Spleen tyrosine kinase (SYK) is a key integrator of intracellular signals triggered by activated
immunoreceptors, including Bcell receptors (BCR) and Fc receptors, which are important for the development and
function of lymphoid cells. Given the clinical efficacy of Bcell depletion in the treatment of rheumatoid arthritis and
multiple sclerosis, pharmacological modulation of Bcells using orally active small molecules that selectively target
SYK presents an attractive alternative therapeutic strategy.
Methods: A SYK inhibitor was developed and assayed in various in vitro systems and in the mouse model of
collagen-induced arthritis (mCIA).
Results: A novel ATP-competitive inhibitor of SYK, 6-[(1R,2S)-2-Amino-cyclohexylamino]-4-(5,6-dimethyl-pyridin-2-
ylamino)-pyridazine-3-carboxylic acid amide, designated RO9021, with an adequate kinase selectivity profile and oral
bioavailability, was developed. In addition to suppression of BCR signaling in human peripheral blood mononuclear
cells (PBMC) and whole blood, FcγR signaling in human monocytes, and FcεR signaling in human mast cells,
RO9021 blocked osteoclastogenesis from mouse bone marrow macrophages in vitro. Interestingly, Toll-like Receptor
(TLR) 9 signaling in human Bcells was inhibited by RO9021, resulting in decreased levels of plasmablasts,
immunoglobulin (Ig) M and IgG upon B-cell differentiation. RO9021 also potently inhibited type I interferon
production by human plasmacytoid dendritic cells (pDC) upon TLR9 activation. This effect is specific to TLR9 as
RO9021 did not inhibit TLR4- or JAK-STAT-mediated signaling. Finally, oral administration of RO9021 inhibited
arthritis progression in the mCIA model, with observable pharmacokinetics (PK)-pharmacodynamic (PD) correlation.
Conclusions: Inhibition of SYK kinase activity impinges on various innate and adaptive immune responses.
RO9021 could serve as a starting point for the development of selective SYK inhibitors for the treatment of
inflammation-related and autoimmune-related disorders.* Correspondence: chliao2000@gmail.com
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Effective treatments of human autoimmune diseases,
which are complex and heterogeneous by nature, re-
quire therapeutic perturbation or restoration of multiple
redundant and distinct mechanisms, or a master regula-
tor of such pathways. In the case of rheumatoid arthritis
(RA) pathogenesis, the critical role of the adaptive im-
mune response and proinflammatory cytokines has been
unequivocally established by the efficacy of marketed
biologics targeting tumor necrosis factor (TNF) alpha,
interleukin (IL)-6, CD20 (B-cell depletion) and CD80/86
(modulation of T-cell co-stimulation). However, their effi-
cacy are capped by limited efficacy, with 40% of patients
never responding to treatments and only 20% of patients
experiencing a major reduction in disease activity [1].
There thus remains a tremendous unmet clinical need
for more effective therapeutic strategies, with a goal of
sustained remission for a greater number of patients
with RA.
Current therapeutic strategies pursued by the bio-
pharmaceutical industry include those that target the
janus kinase (JAK)-mediated signaling pathway, lympho-
cyte migration using chemokine CCR1 antagonist, and
B cells using either depleting antibodies that recognize
common cell surface antigens, such as CD22 and CD19,
or blocking antibodies to B-cell survival factor such as
B-cell activating factor (BAFF) or a proliferation-
inducing ligand (APRIL). Although the pan-JAK inhibi-
tor tofacitinib was recently approved by the US Food
and Drug Administration for the treatment of RA, it is
still not superior to the biologics in terms of efficacy and
safety. For other autoimmune diseases that are in dire
need of safer and/or more effective therapies, the anti-
BAFF antibody belimumab, despite showing marginal ef-
ficacy in clinical trials, was approved for treatment of
systemic lupus erythematous (SLE). Disappointingly, an-
other anti-BAFF antibody (tabalumab) also did not show
adequate efficacy in a phase 3 RA trial (Elli Lilly news
release, 13 December 2012). Whether an agent that neu-
tralizes both BAFF and APRIL will produce better re-
sults remains to be seen.
Other emerging approaches target key enzymes involved
in mediating multiple signal transduction pathways. One
such enzyme is the spleen tyrosine kinase (SYK), which is
a master regulator in coupling activated immunoreceptors
to the mobilization of downstream signal transduction
cascades that affect diverse biological functions. One of
the best characterized modules in the transmission of
B-cell receptor (BCR) activating signals within B cells is
the SYK–Bruton’s tyrosine kinase (BTK) axis, where BTK
acts as an essential downstream effector of SYK in regula-
ting both the maturation and survival of the B-cell lineage.
Given the central role of SYK in transmission of antigen
receptor signals that are critical for autoantibodyproduction and the various innate immune effector func-
tions, pharmacological inhibition of the catalytic function
of SYK is expected to have pleiotropic anti-inflammatory
effects and to impact multiple steps in the pathogenesis of
autoimmune disorders [2]. This could result in greater
and/or broader therapeutic efficacy as well as increased
coverage of the patient population, and perhaps a de-
creased propensity to lose therapeutic efficacy over time.
Here, we describe the discovery and characterization
of a novel ATP-competitive inhibitor of SYK: 6-[(1R,2S)-
2-amino-cyclohexylamino]-4-(5,6-dimethyl-pyridin-2-
ylamino)-pyridazine-3-carboxylic acid amide, designated
RO9021. The inhibitor RO9021 has reasonable kinase
selectivity profile, potency and oral bioavailability and
is capable of suppressing various innate and adaptive
immune responses in vitro, as well as disease progression
in the mouse collagen-induced arthritis (mCIA) model.
RO9021 could thus serve as a lead candidate for further
development of selective SYK inhibitors for the potential
treatment of immunological disorders.
Materials and methods
Experimental animals
C57BL/6 and DBA/1J adult mice were purchased from
Charles River Laboratories (Wilmington, MA, USA). All
animal procedures were approved by and conducted in
accordance with the Institutional Animal Care and Use
Committee guideline at Hoffmann-La Roche (Nutley,
NJ, USA).
Chemical compounds and reagents
SYK inhibitor RO9021 was designed and synthesized at
Hoffmann-La Roche. Tofacitinib citrate (CP-690,550)
was acquired from Selleck Chemicals LLC (Houston,
TX, USA). All chemical reagents were purchased from
Sigma-Aldrich (St Louis, MO, USA), antibodies for flow
cytometric analysis were acquired from BD Biosciences
(San Jose, CA, USA), cytokines were acquired from
R&D Systems (Minneapolis, MN, USA) and antibodies
for western blots were acquired from Cell Signaling
Technologies (Danvers, MA, USA), unless indicated
otherwise.
SYK inhibitor, kinase selectivity and kinase activity assays
RO9021 was designed and synthesized at Hoffmann-La
Roche, Inc. Specificity to SYK was assessed by an ATP
competitive binding assay at 1 μM compound concen-
tration at KINOMEscan Inc. (San Diego, CA, USA) [3].
The inhibitory potency to SYK was determined in a
radiometric assay using inactive SYK kinase. Briefly, SYK
protein (Invitrogen, Carlsbad, CA, USA) was dephos-
phorylated by PTP1B phosphatase (Invitrogen) and then
the reaction was initiated by the addition of substrate
cocktail that contained 20 μM ATP, 0.025 μCi ATP-γ-33P
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biotinylated synthetic peptide (Biotin-EPEGDYEEVLE;
Biomer Technology, Pleasanton, CA, USA) [4-6]. The
reaction was carried out for 30 minutes and resulting
33P incorporation was determined by top counter.
Co-crystallization of SYK and RO9021
SYK (356 to 635) containing a kinase domain was cloned,
expressed, and purified, and co-crystallization of SYK
and RO9021 was carried out following the protocol as
reported previously by our group [7,8]. The structure has
been deposited in the Protein Data Bank [PDB:4GFG].
Calcium influx fluorometric imaging plate reading assay
Human B-cell lymphoma cell line Ramos (CRL-1596;
American Type Culture Collection, Manassas, VA, USA)
or T-cell lymphoma cell line Jurkat (CRL-2063; American
Type Culture Collection) were loaded with calcium dye
(BD Biosciences) for the assay. Baseline fluorescence was
recorded for about 20 seconds followed by stimulation
with mouse anti-human IgM (10 μg/ml, clone M2E6;
Antibody Solutions Inc., Mountain View, CA, USA) for
Ramos cells or mouse anti-human CD3 (10 μg/ml; BD
Biosciences) for Jurkat cells, and the maximal fluorescent
counts in each well were recorded.
Detection of the phosphorylation of BTK, PLCγ2, ERK
and AKT
Ramos cells were pretreated with RO9021 followed by
stimulation with goat F(ab′)2 anti-human IgM (10 μg/ml;
Southern Biotech, Birmingham, AL, USA). The protein
phosphorylation was detected with rabbit antibodies of
anti-phospho-BTK(Y223) (Epitomics Inc., Burlingame, CA,
USA), anti-phospho-PLCγ2(Y1217), anti-phospho-ERK
(T202/Y204) or anti-phospho-AKT(S473).
Flow cytometric analysis of CD69 upregulation in B cells
Heparinized blood was collected from healthy volunteers
and pre-incubated with RO9021 followed by stimulation
with goat F(ab′)2 anti-human IgM (50 μg/ml) overnight.
The samples were stained with PE mouse anti-human
CD20 and APC mouse anti-human CD69. The percen-
tage of activated (CD69hi) B cells was determined using
unstimulated (negative control) and stimulated (positive
control) samples as references.
Fc receptor-mediated and lipopolysaccharide-mediated
TNFα production in human monocytes
Peripheral blood mononuclear cells (PBMCs) were isolated
by centrifugation from heparinized blood in a Vacutainer
CPT Cell Preparation Tube (BD Biosciences). PBMCs
were cultured for 1 to 2 hours to allow monocytes to
adhere, and nonadherent cells were washed away. The
monocytes were stimulated with human IgG-coated(Jackson Immunology, West Grove, PA, USA) copo-
lymer microsphere beads (Thermo Scientific, Fremont,
CA, USA) or lipopolysaccharide (1 ng/ml; Sigma-Aldrich)
for 4 hours. TNFα levels in supernatants were deter-
mined by enzyme-linked immunosorbent assay kits (BD
Biosciences).
IgE-induced histamine release in human mast cells
The method has been reported previously by our group [9].
Briefly, human cord blood-derived CD34+ hematopoietic
stem cells (AllCells, Emeryville, CA, USA) were cultured
in a serum-free StemPro-34 medium (Invitrogen) with
stem cell factor (100 ng/ml) and IL-6 (50 ng/ml) for 8
weeks followed by 5-day stimulation with IL-4 (10 ng/ml).
For measuring histamine release, cells were sensitized with
0.1 μg/ml anti-4-hydroxy-3-nitrophenylacetyl hapten IgE
(Serotec, Raleigh, NC, USA) overnight, and then cross-
linked with 1 μg/ml NP(30)-BSA (Biosearch Technologies,
Novato, CA, USA) for 30 minutes. Supernatants were
collected and assayed for histamine release using a hista-
mine enzyme immunoassay (Oxford Biomedical Research,
Rochester Hills, MI, USA). The percentage of histamine
release was calculated by comparing various treatments
with positive control.
Flow cytometric analysis of phosphorylated STAT1
and STAT5
Human PBMCs were pre-incubated with compound for
30 minutes followed by 20 minutes stimulation with IL-2
(100 ng/ml) for signal transducers and activators of tran-
scription 5 (STAT5) phosphorylation or IFNγ (100 ng/ml)
for STAT1 phosphorylation. For IL-2-induced STAT5
phosphorylation, cells were stained with FITC anti-human
CD3 and Alexa Fluor 647 anti-STAT5(pY694), and quanti-
tated pSTAT5 fluorescence intensity gated on the CD3+
T-cell population. For IFNγ-induced STAT1 phospho-
rylation, cells were stained with PE anti-human CD14
(Beckman Coulter, Indianapolis, IN, USA) and Alexa
Fluor 647 anti-STAT1 (pY701), and quantitated pSTAT1
fluorescence intensity gated on CD14+ monocytes/
macrophages.
Mouse bone marrow macrophage-derived
osteoclastogenesis
Bone marrow cells were obtained from C57BL/6 mouse
tibiae and suspended in culture medium supplemented
with monocyte colony-stimulating factor (100 ng/ml)
for 16 hours. Nonadherent cells were harvested and fur-
ther cultured with monocyte colony-stimulating factor
(M-CSF) (100 ng/ml) and receptor activator of nuclear
factor kappa-B ligand (100 ng/ml) for 3 days to induce
the formation of multinuclear osteoclasts [10-13]. The
cells were stained using a tartrate-resistant acid
Liao et al. Arthritis Research & Therapy 2013, 15:R146 Page 4 of 14
http://arthritis-research.com/content/15/5/R146phosphate (TRAP) staining kit (Sigma, St Louis, MO,
USA). TRAP+ multinuclear cells were counted for each
well under a microscope.
Toll-like receptor 9-mediated B-cell activation and
plasmablast differentiation
Human B cells were enriched using RosetteSep® human
B-cell enrichment cocktail (StemCell Technologies,
Vancouver, Canada), followed by stimulation with
ODN2006 (1 μM; InvivoGen, San Diego, CA, USA)
and IFNα (20 ng/ml) for 3 days. The IL-6 production
in the supernatant was measured by AlphaLISA kit
(Perkin Elmer). The live cells were quantitated by the
CellTiter-Glo® luminescent Cell Viability Assay kit
(Promega, Madison, WI, USA).
Human B cells were differentiated with ODN2006
(50 nM) and IL-2 (10 ng/ml) for 6 days. The differen-
tiated cells were stained with V450 anti-CD38, FITC
anti-CD20, PE anti-CD19 and APC intracellular IgM.
The plasmablasts were identified as CD19+CD38+CD20–
IgM+ cells. The production of IgG and IgM was quanti-
tated by AlphaLISA.
Toll-like receptor 9-mediated plasmacytoid dendritic cell
activation
Human plasmacytoid dendritic cells (pDCs) were isolated
by negative selection from PBMCs with the human pDC
Isolation Kit (Miltenyi Biotec, Auburn, CA, USA). The
purity was confirmed with CD303 (BDCA-2; Miltenyi
Biotec) staining and stimulated with ODN2216 (1 μM) for
2 days. The production of IFNα and TNFα was measured
by AlphaLISA.
Murine collagen-induced arthritis model
The mCIA model has been reported previously [9].
Briefly, DBA1/J male mice were injected intradermally
with 0.1 ml bovine type II collagen (100 μg; Chondrex
Inc., Redmond, WA, USA) and complete Freund’s adju-
vant (200 μg; Difco, Detroit, MI, USA) followed by
second immunization on day 21 with bovine type II col-
lagen and incomplete Freund adjuvant. RO9021 was
administered orally, randomized into different groups
(14 mice/groups), every day for 14 days starting on the
day after second immunization. Clinical arthritis scores
(1 to 4) of individual paws were assessed and the arth-
ritic index for each mouse was determined by adding
the individual scores of all four paws. The level of cyto-
kines in serum was determined by Luminex analysis
(Millipore, Billerica, MA, USA).
Histopathological analysis
Hind paws from CIA mice were collected into 10% neu-
tral buffered formalin. After decalcification in 10% for-
mic acid, paws were embedded in paraffin, sectioned at8 μm and stained with toluidine blue. Inflammation
(infiltration of inflammatory cells), pannus, cartilage
damage, and bone resorption were scored in a double-
blinded fashion by a board-certified pathologist at Boulder
BioPATH, Inc. (Boulder, CO, USA) using standard cri-
teria, with 0 being normal and 5 being the most severe.
Half-maximal inhibitory concentration determination and
statistical analysis
Half-maximal inhibitory concentration (IC50) values and
dose/concentration response curves were determined by
sigmoidal dose–response curve fitting using XLFit (IDBS,
Alameda, CA, USA) or Prism (GraphPad Inc., La Jolla,
CA, USA). In most studies, the IC50 values reported were
the average from at least two studies conducted with
samples in replicate. For in vivo studies, one-factor and
two-factor comparisons were performed, respectively,
using one-way or two-way analysis of variance plus
Dunnett’s post test.
Results
Biochemical characterization of RO9021, a potent and
selective SYK inhibitor
RO9021 (Figure 1A) was identified following extensive
medicinal chemistry optimization of a lead identified
from high-throughput screening of Roche’s proprietary
chemical compounds library. In a SYK kinase enzymatic
assay, RO9021 potently inhibited SYK kinase activity
with an average IC50 of 5.6 nM (Figure 1B). Selectivity
of RO9021 against a panel of 451 wild-type and mutant
protein kinases was assessed using an ATP binding site
competition assay developed by KINOMEscan Inc. [3].
As shown in the dendrogram depicting a qualitative
overall impression of kinase selectivity, RO9021 was
highly selective for SYK enzyme (largest circle, marked
blue) at 1 μM concentration (Figure 1C). The selectivity
of RO9021 was quantitatively expressed as a selective
score (S-score), which was calculated by dividing the
number of RO9021-bound kinases by the total number
of wild-type protein kinases tested (n = 392), excluding
mutant variants. The S-score is an unbiased measure
that enables quantitative comparisons between com-
pounds. A lower S-score means higher selectivity [14].
As shown in Figure 1D, RO9021 is a highly selective
SYK inhibitor with low S-scores of 0.003 for S(99) and
0.015 for S(90), indicating that SYK is the only kinase
with 99% competition with RO9021 in a total of 392
tested kinases. There were only a total of seven kinases,
including SYK, having more than 90% competition with
RO9021 (listed in Additional file 1: Figure S1).
The expected binding mode of RO9021 was confirmed
by the determination of the co-crystal structure of
RO9021 and the SYK protein kinase domain (Figure 1E;












S(65) 35 392 0.089
S(90) 6 392 0.015
S(99) 1 392 0.003
E.
Figure 1 Structure, potency and selectivity of a novel spleen tyrosine kinase inhibitor, RO9021. (A) Compound structure of RO9021,
6-((1R,2S)-2-amino-cyclohexylamino)-4-(5,6-dimethyl-pyridin-2-ylamino)-pyridazine-3-carboxylic acid amide. (B) Inhibition of spleen tyrosine kinase
(SYK) enzymatic activity, measured by incorporation of 33P-ATP into SYK substrate peptide. The half-maximal inhibitory concentration (IC50) is
reported as the average value of three independent assays. (C) Kinome selectivity of RO9021. RO9021 was profiled against 392 nonmutant kinases
by KinomeScan and presented as a kinome dendrogram. Circle size is proportional to percentage inhibition at the test concentration (1 μM):
largest circle, 99% inhibition; medium circle, 90 to 99% inhibition; smallest circles, 51 to 90% inhibition. Arrow, SYK kinase (blue circle).
(D) Selectivity score of RO9021. The selectivity score is a quantitative measure of compound selectivity, calculated by dividing the number of
kinases that compounds bind to by the total number of distinct kinases tested, excluding mutant variants. (E) Structural basis of RO9021
selectivity. Crystal structure of RO9021 bound to SYK. Orange dotted lines, possible hydrophobic interactions between RO9021 and the Pro455/
Gly454 region (surface shaded red).
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secondary amine with the carboxy side chain of D512 of
SYK, while the primary amine forms a hydrogen bond
with the backbone of Arg498 and a salt bridge with
the other oxygen of the D512 side chain. The 5,6-
dimethylpyridine group of RO9021 projected out over to
Gly454 and Pro455, making hydrophobic contacts. A
proline at this position (Pro455) in the ATP binding site is
rare in kinases, present in only nine out of a total of 433kinases, so these interactions probably contribute to the
high selectivity of this compound for SYK [15].
RO9021 selectively suppresses B-cell receptor signaling
Since SYK is best studied as a key mediator of BCR acti-
vating signals within B cells, we first evaluated the effect
of RO9021 in blocking BCR-dependent responses. The
human B-cell line, Ramos, was pretreated with 1 μM
RO9021 prior to anti-IgM antibody-induced cross-linking
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Figure 2 Inhibition of B-cell receptor and Fc Receptor pathways by RO9021. (A) RO9021 inhibited phosphorylation of PLCγ2(Y1217), BTK
(Y223), AKT(S476) and ERK(p42/44) (T202/Y204) in anti-IgM stimulated Ramos cells. The levels of total Bruton’s tyrosine kinase (BTK) and β-tubulin were
used as loading controls. (B) RO9021 suppressed anti-IgM mediated calcium flux in Ramos cells (Ramos-BCR, squares), but not anti-CD3-mediated
calcium flux in Jurkat cells (Jurkat-TCR, triangles). Intracellular calcium concentrations were measured using a calcium-sensitive fluorescent dye and
presented as calculated percentage inhibition. (C), (D) Inhibition of anti-IgM-induced CD69 expression in human peripheral blood mononuclear cells
(PBMCs) (C) and whole blood (D). Data were in duplicate and are shown as mean ± standard deviation (SD). (E) RO9021 inhibited FcγR signaling
(human IgG-coated beads, dots), but not toll-like receptor-4 (TLR4)-induced TNFα production (lipopolysaccharide (LPS), triangles) in human monocytes.
Percentage of inhibition by compound presented. Data were in quadruplicate and are shown as mean ± SD. (F) Inhibition of histamine release in
human mast cells induced by anti-4-hydroxy-3-nitrophenylacetyl hapten (NP) IgE and NP. Anti-NP IgE and NP cross-linking-induced a robust histamine
release (cells alone, triangle; IgEx, inverted triangle). RO9021 attenuated IgE-NP-induced histamine release in a concentration-dependent manner
(circle). Data were in triplicate and are shown as mean ± SD.
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ponents was assessed by western blot using phospho-
specific antibodies. As shown in Figure 2A, treatment with
RO9021 inhibited anti-IgM induced phosphorylation of
BTK, PLCγ2, AKT and ERK, indicating that blockade of
SYK kinase activity by RO9021 resulted in attenuation of
BCR downstream signaling cascade.
Next, we examined the effect of RO9021 in several
functional outcomes of BCR signaling using both human
B-cell lines and primary cells. Consistent with the known
biology of SYK, RO9021 blocked anti-IgM-activated
calcium flux in Ramos B-cell line with an IC50 value of
78 ± 21 nM. This effect is specific to BCR signaling
because RO9021 showed about 12-fold potency shift
(IC50 = 910 ± 270 nM) in blocking T-cell receptor (anti-
CD3)-induced calcium flux in Jurkat, a human T-cell line
(Figure 2B). Finally, when tested in human PBMCs or
whole blood, RO9021 inhibited BCR-dependent cell sur-
face CD69 expression in CD20+ B cells with IC50 values of
83 nM and 87 nM, respectively (Figure 2C,D).A.
B.
Figure 3 Marginal effect of RO9021 in the JAK–STAT pathway. Human
the janus kinase (JAK) inhibitor tofacitinib and then stimulated with IL-2 to
STAT1 phosphorylation in CD14+ monocytes/macrophages (B). Left panels
gray, unstimulated; filled red, stimulated with IL-2 or IFNγ. Blue line, treatm
(tofacitinib). Right panels: concentration-dependent inhibition curves of ROSelective inhibition of Fc receptor signaling in monocytes
and mast cells by RO9021
SYK is also recruited into activated Fc receptor through
an interaction with the phosphorylated ITAM motifs of
the receptor and mediates Fc receptor downstream signal-
ing. We therefore examined the effects of inhibiting SYK
kinase activity with RO9021 on FcγR signaling in human
monocytes and FcεR signaling in human mast cells. As
shown in Figure 2E, the production of the proin-
flammatory cytokine TNFα induced by crosslinking of
FcγR on human monocytes was inhibited by RO9021 with
an IC50 value of 63 ± 19 nM. In contrast, RO9021 had
very weak effect on Toll-like receptor (TLR)-4-dependent
TNFα production (IC50 = 2.9 ± 0.9 μM) in monocytes
stimulated by lipopolysaccharide, indicating that RO9021
blocks the FcγR pathway in a specific manner. Further-
more, RO9021 also displayed a similar inhibitory potency
(IC50 = 22.8 ± 1.7 nM) in a FcεR-mediated mast cell acti-
vation and degranulation assay, as judged by inhibition of
IgE/antigen-induced histamine release (Figure 2F).peripheral blood mononuclear cells were pretreated with RO9021 or
induce STAT5 phosphorylation in CD3+ T cells (A) or IFNγ to induce
, representative overlaid histograms of flow cytometric analysis. Filled
ent with 1 μM RO9021; green line, treatment with 1 μM JAK inhibitor
9021 (dots) and tofacitinib (squares).
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pathway
In addition to SYK, the KINOMEscan analysis revealed that
there were six other kinases with more than 90% competi-
tion with RO9021 (Additional file 1: Figure S1). Of particu-
lar interest are JAK1 and JAK3 because pharmaceutical
inhibitors of these family members have demonstrated clin-
ical efficacy in RA trials. We therefore examined whether
RO9021 had any cellular JAK activity. To that end, PBMCs
were pretreated with RO9021 prior to stimulation with ei-
ther IL-2 to activate the JAK1/3–STAT5 pathway in T cells
or IFNγ to activate the JAK1/2–STAT1 pathway. As a posi-
tive control, the JAK inhibitor tofacitinib (CP 690550) was
included in the analysis. As shown in Figure 3A, phospho-
STAT5 staining in the CD3+ T-cell population was in-
duced by IL-2 stimulation (filled red histogram vs.
nonstimulated filled gray histogram). At 1 μM, tofacitinib
completely blocked the phosphorylation of STAT5 (green
line) whereas RO9021 had no significant effect (blue line).
Concentration-dependent inhibitory curves (Figure 3A,
right) also showed significant potency shift between
tofacitinib and RO9021, with average IC50 values of 31 ±
13 nM and 1.32 ± 0.66 μM, respectively. Similarly, in
IFNγ-treated CD14+ monocytes, RO9021 had no effect
on the phosphorylation of STAT1, except at the highest
concentration tested (10 μM) (Figure 3B). In contrast,
tofacitinib inhibited STAT1 phosphorylation in a
concentration-dependent manner with an average IC50A. -
Figure 4 Dose-dependent inhibitory effects of RO9021 on osteoclasto
phosphate (TRAP) staining showing receptor activator of nuclear factor kap
mediated osteoclastogenesis from mouse bone marrow macrophages (BM
positive controls labeled as (–) RANK-L (upper left) and (+) RANK-L (upper r
upper right corner of each image. (B) TRAP+ multinuclear osteoclasts were
osteoclastogenesis was presented. Results were in triplicate and are plotted
inhibitory concentration.value of 81 ± 50 nM. RO9021 thus did not appear to ap-
preciably inhibit the JAK–STAT pathway in the cell, fur-
ther supporting the selectivity of the compound.
SYK kinase activity is essential for osteoclastogenesis
Bone destruction is one of the hallmarks of RA and is
mainly attributed to an abnormal activation and differen-
tiation of macrophages into osteoclasts that mediate bone
erosion [1,16-18]. We therefore assessed the effects of
RO9021 on osteoclastogenesis using mouse bone marrow-
derived macrophages. Mouse bone marrow macrophages
were differentiated by treatment with soluble receptor
activator of nuclear factor kappa-B ligand and monocyte
colony-stimulating factor in the presence of RO9021 for
about 3 days. As shown in Figure 4, exposure to RO9021
abrogated the formation of multinuclear TRAP+ osteoclasts
in a concentration-dependent manner; TRAP+ cells were
barely detectable in the presence of more than 0.4 μM
RO9021. The results suggest inhibition of SYK kinase activ-
ity may prevent bone erosion in arthritis, which is consist-
ent with previous SYK knockout mice studies [19-23].
RO9021 reveals a novel role for SYK in Toll-like receptor
9-dependent signaling
As BTK has been implicated in TLR signaling [24,25],
we next sought to explore the kinase function of SYK in
TLR9-mediated responses in human B cells and pDCs
with selective SYK inhibitor.B.






























genesis. (A) Representative images of tartrate-resistant acid
pa-B ligand (RANK-L) and monocyte colony-stimulating factor (M-CSF)
M). Osteoclasts were shown as TRAP+ multinuclear cells. Negative and
ight), respectively. The concentration of RO9021 was labeled on the
counted under a microscope and percentage of inhibition on
as mean ± standard deviation. IC50, half-maximal
Figure 5 Inhibition of Toll-like receptor-9 pathway in human B cells and plasmacytoid dendritic cells by RO9021. (A), (B) Human B cells
were stimulated with CpG-B (ODN2006) and IFNα for 2 days. Production of IL-6 (A) and B-cell proliferation (B) was blocked by RO9021. The
proliferation was presented by total alive cells, which were quantitated by Celltiter Glow as relative luminescent units. (C) RO9021 inhibited
human plasmablast differentiation. Human B cells were differentiated with ODN2006 and IL-2 for 6 days. The plasmablasts were identified as
CD19+CD38+CD20– cells and presented as the percentage in total CD19+ B cells. The levels of IgM, IgG and IL-6 in the supernatants were also
blocked by RO9021. (D), (E) RO9021 blocked Toll-like receptor 9 (TLR9)-mediated cytokine production in human plasmacytoid dendritic cells
(pDCs). Purified pDC cells were stimulated with CpG-A (ODN2216) for 2 days. The production of IFNα (D) and TNFα (E) in supernatant were
determined. Data were in duplicate and are shown as mean ± standard deviation. Statistical analysis of each treatment compared with the
positive group was performed by Student’s t test. *P <0.05; **P <0.01; ***P <0.001; ns, not statistically significant. Plots shown are representative
of four independent experiments tested in different donors. IC50, half-maximal inhibitory concentration.
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http://arthritis-research.com/content/15/5/R146Interestingly, we found that the kinase function of SYK
was important for mediating TLR9 responses. As demon-
strated previously, IFNα when used in combination with
TLR9 ligand, ODN2006, synergistically activated B cells as
measured by the production of IL-6 [26,27], which was
inhibited by RO9021 (Figure 5A; IC50 = 222 ± 47 nM).
In addition, TLR9-dependent B-cell proliferation was
also dose-dependently inhibited by RO9021 (Figure 5B;
IC50 = 159 ± 28 nM).
We next differentiated B cells with CpG (ODN2006)
and IL-2 in the presence of different concentrations of
RO9021. After 6 days of culture, a significant percen-
tage of B cells (~30%) proliferated and differentiated
into CD19+CD38+CD20– and intracellular IgM-positive
plasmablast cells. Treatment with RO9021 blocked
the generation of plasmablast cells in a concentration-
dependent manner (Figure 5C). Consistent with the
observed decreased percentage of plasmablast cells, the
production of IgM, IgG, and IL-6 in the supernatant
was also reduced by RO9021 (Figure 5C).
As pDCs are the main source for IFNα, we next exa-
mined the effect of RO9021 on TLR9-mediated IFNα pro-
duction in pDCs. Purified human pDCs (CD303+) were
stimulated with ODN2216 for 2 days and the levels of
IFNα and TNFα were measured. As shown in Figure 5D,
E, IFNα was highly produced by pDCs upon TLR9 activa-
tion, relative to the small amount of TNFα detected.
Importantly, RO9021 inhibited the production of both
cytokines in a concentration-dependent fashion.
RO9021 inhibits progression of murine collagen-induced
arthritis
Based on the above findings that SYK inhibition by
RO9021 is able to impinge on several innate and adaptive
immune responses, we speculated that the compound
should have therapeutic efficacy in an autoimmune
disease model. Furthermore, RO9021 showed reasonable
in vivo pharmacokinetic profiles after single oral adminis-
tration (Table 1 and Additional file 1: Figure S3). No sig-
nificant inhibitions of CYP450 isozymes (IC50 >50 μM)
and hERG (IC20 = 5.5 μM) were observed at pharmaco-
logical concentrations (data not shown).
To this end, we evaluated RO9021 in the mCIA model
of RA. As shown in Figure 6A, RO9021 administered
orally at 5 and 45 mg/kg daily, starting on the day of theTable 1 Pharmacokinetics profile of single oral dosing
RO9021 in mouse
Dose Cmax (nM) Tmax (hours) T1/2 (hours) AUC (hour*nM)
45 mg/kg 5,763.69 0.50 3.54 35,804.26
5 mg/kg 694.52 1.00 4.34 3,847.84
Cmax, maximum plasma concentration; Tmax, time after administration of a
drug when the maximum plasma concentration is reached; T1/2, half-life;
AUC, area under the curve.second immunization (that is, day 21), for 14 days in-
hibited arthritis progression in a dose-dependent manner
as measured by the clinical scores. There was significant
efficacy on arthritis in both the 5 and 45 mg/kg dosing
groups compared with the vehicle group. As shown in
photomicrographs (Figure 6B) and quantitation (Figure 6C)
from histopathological analysis, vehicle-treated, but not
RO9021-treated, mice had severe inflammation and cartil-
age damage with pannus and resorption in the ankle and
all digit joints. Notably, measured levels of cytokines IL-6
and KC(CXCL1) in mouse serum were also markedly re-
duced after 14 days of treatment with RO9021 (Figure 6D).
To demonstrate on-target inhibition by RO9021 and the
pharmacokinetics and pharmacodynamics relationship,
mouse blood samples were collected at 2, 5 and 24 hours
post compound dosing. As shown in Figure 6E, pharma-
codynamics effects based on cell-surface CD69 expression
on B cells (B220+), as judged by ex vivo stimulation with
anti-IgD, were consistent with pharmacokinetics analysis
of compound exposure. RO9021 inhibited anti-IgD-
induced CD69 expression on B cells at 2-hour and 5-hour
time points, but not at the 24-hour time point, suggesting
5-hour compound coverage was sufficient to significantly
impact disease progression in this model.
Discussion
Current biologic agents have not been able to break the
ceiling in terms of delivering better and broader efficacy
for treatment of autoimmune diseases. Given this persis-
tent unmet need and the promise of multipathway inhi-
bition to deliver breakthrough efficacy, pharmacological
modulation of intracellular signaling components with
small molecule agents offers an attractive alternative
therapeutic strategy, provided the risk/benefit profile is
acceptable. In this regard, the SYK–BTK axis is an attrac-
tive target because it is critical for antigen receptor signa-
ling, abnormal regulation of which has been implicated in
the pathogenesis of several autoimmune diseases, inclu-
ding RA and SLE [28].
Among the reported agents targeting the SYK, the in-
hibitor fostamatinib (R788) has demonstrated reduced
clinical efficacy compared with other therapeutic agents.
In our hands, however, R788 is not a very selective kinase
inhibitor, inhibiting one-half of the kinome in the
KinaseScan assay, including JAK and vascular endothelial
growth factor receptor (data not shown), which is con-
sistent with previous reports [15,29], suggesting that the
clinical activities of R788 are not solely attributed to SYK
inhibition. Some of the off-target activities might also
account for the observed adverse effects in clinical trials,
including high blood pressure, which is due to vascular
endothelial growth factor receptor inhibition. R788 is also
a relatively weak SYK inhibitor in whole blood assays,
which is potentially attributed to high plasma protein
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Figure 6 Oral administration of RO9021 abrogated collagen-induced arthritis in mice. (A) Dose-dependent attenuation of clinical scores by
RO9021 (n = 14/group). ***P <0.001 compared with vehicle-treated group. po, per orally. (B) Representative toluidine blue-stained paraffin section
of hind paws of vehicle (left upper), 5 mg/kg RO9021 (left bottom) and 45 mg/kg RO9021 (right bottom) treated mice. Photomicrograph of naïve
mice also shown (right upper). Intense blue staining within joint space (arrows) indicated representative affected joints with inflammation and
pannus formation. (C) Histopathological quantitation of inflammation, pannus formation, cartilage damage, and bone resorption in the hind paws
of a subgroup of mice (n = 15/group). *P <0.05. (D) Serum level of IL-6 and KC(CXCL1) after 14 days of treatment with vehicle or RO9021.
***P <0.001 compared with vehicle-treated group. (E) Inhibition of anti-IgD induced CD69 expression in ex vivo whole blood assay at 2 and 5
hours post dose, but not at 24 hours post dose. CD69 expression in B220+ cells was induced ex vivo with anti-IgD in terminal whole blood from
subgroups of mice. CD69 expression in unstimulated blood (inverted triangle) was also examined and used as baseline control (n = 5/group).
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be necessary to address the mechanism of action and
evaluate the efficacy as well as any potential on-mechanism
toxicity associated with SYK inhibition in clinical trials.
To this end, we have developed an alternative chemical
scaffold of SYK inhibitor, designated RO9021. The protein
kinase selectivity profile of RO9021 was assessed by the
widely accepted KinomeScan method, which utilizes a
proprietary active site-directed competition binding assay
to quantitatively measure interactions between testcompounds and more than 450 human kinases and
disease-relevant mutant variants. As shown in Figure 1 and
Additional file 1: Figure S1, beside SYK with 99% competi-
tion only six protein kinases, including JAK1 and JAK3,
have more than 90% competition, indicating that RO9021
has superb selectivity. Since truncated forms of recombin-
ant JAK1 and JAK3 were utilized in the KinomeScan assay,
we examined the ability of RO9021 to inhibit JAK-mediated
signaling in cell-based assays and found the compound had
weak or no activity (Figure 3). In contrast, RO9021
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namely PLCγ2 and BTK, in response to BCR engagement
(Figure 2A), consistent with the known biology of SYK in
BCR signaling. Taken together, these data strongly indicate
that the compound effect in cells is mediated by SYK inhib-
ition. Furthermore, RO9021 has reasonable oral bioavail-
ability profiles and thus can be used to interrogate the
various reported biological roles of SYK in preclinical dis-
ease models. In addition to suppression of BCR signaling in
human PBMCs and whole blood (Figure 2C,D), FcγR sig-
naling in human monocytes (Figure 2E), and FcεR signaling
in human mast cells (Figure 2F), we showed that RO9021
also blocked osteoclastogenesis of mouse bone marrow
macrophages in vitro (Figure 4).
Certain autoimmune diseases, such RA and SLE, arise
from an inappropriate immune response of the body
against self-antigens [1,30,31]. SLE, for instance, is charac-
terized by the loss of tolerance to self-nuclear antigens, the
deposition of immune complexes in tissues, and multiorgan
involvement [32]. Studies have shown that nuclear-acid
sensing pathways implicated in the subversion of the innate
immune response to discriminate between self-antigen and
foreign antigens are those mediated by the TLRs in the
context of SLE pathogenesis [32-34]. BTK, which is a
downstream kinase of SYK, has been implicated in TLR
signaling recently [24,25], whereas the role of SYK in TLR
signaling is not well appreciated. It has been reported that
the TLR9 agonist CpG could induce TLR-9 independent
SYK phosphorylation and activation through actin cytoskel-
eton reorganization, leading to activation of Src family
kinases [35]. Recruitment of SYK to TLR9 and phosphoryl-
ation of TLR9 are required for CpG-induced cytokine pro-
duction. We therefore used RO9021 to study the role of
SYK in TLR9 signaling. Interestingly, the kinase function of
SYK is essential for TLR9-mediated responses in human B
cells (Figure 5A,B,C). Inhibition of SYK kinase function
resulted in a decreased level of plasmablasts, IgM, IgG and
IL-6 upon B-cell differentiation in the presence of TLR9
ligand. In addition, RO9021 also potently inhibited IFNα
production by human pDCs upon TLR9 activation
(Figure 5D). Importantly, the effects on TLR9 responses are
specific because RO9021 did not inhibit TLR4-dependent
TNFα production by human monocytes (Figure 2E) or acti-
vation of the JAK–STAT pathway stimulated with either
IL-2 or IFNγ (Figure 3). Our study showed for the first time
that kinase activity of SYK is critical for TLR9 signaling
pathway in B cells and pDCs.
The role of SYK in TLR signaling in B cells and pDCs
could have significant implication for SYK inhibitors as
therapeutic agents for SLE since the development and pro-
gression of the disease are believed to be driven by the in-
appropriate activation of TLR7, TLR8 and TLR9. Other
studies have indicated that autoimmunity in RA and psoria-
sis also is mediated through one or more of these TLRs[36-41]. In this regard, it is noteworthy that TLR antagonists
such as IRS-954 (TLR7 and TLR9 antagonist) [42,43] and
IMO-8400 (TLR7, TLR8 and TLR9 antagonist) are currently
undergoing clinical trials in SLE.
Consistent with its inhibitory activities in various innate
and adaptive immune responses, oral administration of
RO9021 inhibited arthritis progression in the mCIA
model (Figure 6). Importantly, there was correlation bet-
ween pharmacokinetics analysis of compound exposure
and pharmacodynamics analysis based on anti-IgD-
induced CD69 expression on B cells (B220+), indicating
on-target mode of action. Furthermore, the pharmaco-
dynamics analysis suggests that 5-hour compound cover-
age was sufficient to ameliorate the disease in this model.
Conclusions
The present study collectively suggests RO9021 is a selective,
potent and orally bioavailable small molecule SYK kinase in-
hibitor, which could serve as a promising chemical lead for
the design of clinical SYK inhibitors and could complement
the current arsenal of tools in development for treatment of
inflammation-related and autoimmune-related disorders.
Additional file
Additional file 1: Figure S1 lists kinases with more than 90%
binding efficiency with RO9021 (1 μM) in the KinomeScan assay.
Figure S2 shows the X-ray crystal structure of SYK with front view (A) and
top view (B), showing the ATP binding site with RO9021 bound. Black
dashes, hydrogen bonds; orange dashes, hydrophobic contacts to the
Gly454/Pro455 region. Figure S3 shows the pharmacokinetics profile of
single oral dose of RO9021 in mouse.
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